Prostate Cancer Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Prostate Cancer market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, Myovant Sciences, Sanofi,

[Nevada, United States] - DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Prostate Cancer, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Prostate Cancer Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Prostate Cancer Market Report:
• The Prostate Cancer market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Aragon Pharmaceuticals, Inc. announced that the purpose of their study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival based on conventional or prostate specific membrane antigen-positron emission tomography (PSMA-PET) imaging evaluated by blinded independent central review (BICR).
• In October, 2024: Janssen Research & Development, LLC announced that the purpose of their study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).
• In October, 2024: Clarity Pharmaceuticals Ltd announced that their study aims to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
• In October, 2024: Merck Sharp & Dohme LLC announced that Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01).
• In October, 2024: AstraZeneca announced that their study will assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumor response
• Key Prostate Cancer Companies are as follows: AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, Myovant Sciences, Sanofi,
• Key Prostate Cancer Therapies are as follow: ERLEADA, XTANDI NUBEQA, ZYTIGA, PLUVICTO, TALZENNA, AKEEGA, LYNPARZA, ORGOVYX, JEVTANA, XOFIGO, RUBRACA, CAN-2409, KPG-121, Capivasertib, ARV-110, D-7300, MGC018, MVI-816, 177Lu-PNT2002 (PNT2002), Vudalimab (XmAb20717), 177Lu-DOTA-rosopatamab (TLX591), HC-1119, Cabozantinib, Masitinib, ModraDoc006/r
• Launching multiple stage Prostate Cancer pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Prostate Cancer market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Prostate Cancer Overview:
Prostate cancer is a type of malignancy in the prostate gland, a part of the male reproductive system. Fortunately, most prostate cancers tend to grow slowly and are low-grade with relatively low risk and limited aggressiveness. Prostate cancer is rare in men younger than 40, but the chance of having prostate cancer rises rapidly after age 50.

Prostate Cancer Epidemiology Segmentation:
The Prostate Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Prostate Cancer Total Prevalence
• Prostate Cancer Prevalent Cases by severity
• Prostate Cancer Gender-specific Prevalence
• Prostate Cancer Diagnosed Cases of Episodic and Chronic

For more information about Prostate Cancer companies working in the treatment market, visit https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Prostate Cancer Market Insights
Prostate cancer remains one of the most commonly diagnosed cancers among men globally. Advances in treatment, increasing awareness, and early detection have significantly impacted the Prostate Cancer Market. The market continues to evolve with novel therapies, improved diagnostics, and a growing understanding of the disease. Here is an analysis of the latest Prostate Cancer Market Insights, focusing on drugs uptake, epidemiology, market drivers, and barriers.

Prostate Cancer Drugs Uptake
• Androgens play a key role in the growth of prostate cancer cells, and ADT has long been a standard treatment for advanced prostate cancer. Drugs such as leuprolide (Lupron), goserelin (Zoladex), and degarelix (Firmagon) are commonly used.
• Enzalutamide (Xtandi) and apalutamide (Erleada) are second-generation androgen receptor inhibitors that block androgen signaling more effectively than traditional ADT. They are approved for both metastatic and non-metastatic castration-resistant prostate cancer.
• Abiraterone inhibits CYP17, an enzyme crucial for androgen production. It is used in combination with prednisone to treat both metastatic hormone-sensitive and castration-resistant prostate cancer.
• Olaparib (Lynparza) and rucaparib (Rubraca) are PARP inhibitors approved for prostate cancer with BRCA1/2 mutations or other homologous recombination repair (HRR) gene alterations.
• Radium-223 is a radiopharmaceutical used to treat bone metastases in prostate cancer. It targets bone tumors, delivering localized radiation to prolong survival and alleviate pain.
• Recently approved therapies like lutetium-177 PSMA radioligand therapy offer targeted treatment for metastatic prostate cancer. PSMA is highly expressed on prostate cancer cells, allowing for more precise delivery of treatment.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Prostate Cancer Therapies and Key Companies:
• 177Lu-PSMA-I&T: Curium US LLC
• Apalutamide: Cancer Research Antwerp
• Abiraterone, Prednisone: Janssen Research & Development, LLC
• Abiraterone: Cougar Biotechnology, Inc.
• AAA617: Novartis Pharmaceuticals
• Quinacrine: Cleveland BioLabs
• 18F-Fluciclovine PET CT: Debiopharm International SA
• SR31747A: Sanofi
• 64Cu-SAR-BB: Clarity Pharmaceuticals Ltd
• GTX-006: GTx
• Darolutamide: Bayer
• Leuprolide Mesylate:
• Foresee Pharmaceuticals Co., Ltd.
• 177Lu-PSMA-617, 68Ga-PSMA-11: Novartis Pharmaceuticals

Prostate Cancer Epidemiology:
Prostate cancer is the second most common cancer in men worldwide. The incidence of prostate cancer varies by region, with the highest rates observed in North America, Europe, and Oceania. In 2023, approximately 1.4 million new cases of prostate cancer were diagnosed globally. Prostate cancer primarily affects older men, with the majority of cases occurring in men over the age of 65. Risk factors include age, genetics, family history, and lifestyle factors such as diet and physical inactivity.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Prostate Cancer Market Drivers:
• Rising Incidence and Aging Population
• Advancements in Diagnostics
• Innovative Drug Development
• Expanding Treatment Options for Advanced Disease

Prostate Cancer Market Barriers:
• High Cost of Treatment
• Adverse Side Effects
• Limited Access in Low- and Middle-Income Countries
• Regulatory and Reimbursement Challenges

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Prostate Cancer Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Prostate Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, Myovant Sciences, Sanofi,
• Key Prostate Cancer Therapies: ERLEADA, XTANDI NUBEQA, ZYTIGA, PLUVICTO, TALZENNA, AKEEGA, LYNPARZA, ORGOVYX, JEVTANA, XOFIGO, RUBRACA, CAN-2409, KPG-121, Capivasertib, ARV-110, D-7300, MGC018, MVI-816, 177Lu-PNT2002 (PNT2002), Vudalimab (XmAb20717), 177Lu-DOTA-rosopatamab (TLX591), HC-1119, Cabozantinib, Masitinib, ModraDoc006/r
• Prostate Cancer Therapeutic Assessment: Current marketed and emerging therapies
• Prostate Cancer Market Dynamics: Prostate Cancer Market drivers and Prostate Cancer barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Prostate Cancer Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Prostate Cancer market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Executive Summary of Prostate Cancer
4 Key Events
5 Epidemiology and Market Forecast Methodology of Prostate Cancer
6 Prostate Cancer Market Overview at a Glance
7 Disease Background and Overview
8 Treatment and Management of Prostate Cancer
9 Treatment Guidelines
10 Epidemiology and Patient Population
11 Patient Journey
12 Marketed Therapies
13 Emerging Therapies
14 Prostate Cancer: Seven Major Market Analysis
15 Unmet Needs
16 SWOT Analysis
17 KOL Views
18 Market Access and Reimbursement
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.